Evidence map›Paper›PMID 34752333›Full record

ArticleMethods in cell biology2021

Strategies for targeting cell surface proteins using multivalent conjugates and chemical biology.

Shivani Sachdev, Chino C Cabalteja, Ross W Cheloha

Abstract read
In one paragraph

Article in Methods in cell biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shivani SachdevNational Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), Laboratory of Bioorganic Chemistry, Bethesda, MD, United States.
Chino C CabaltejaNational Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), Laboratory of Bioorganic Chemistry, Bethesda, MD, United States.
Ross W ChelohaNational Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), Laboratory of Bioorganic Chemistry, Bethesda, MD, United States. Electronic address: ross.cheloha@nih.gov.

Funding

New tools from chemistry and antibodies to address receptor functionZIADK075157 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI CHELOHA, ROSS · 2021 to 2025
$6.6M
Intramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK075157
6 · The paper itself

Abstract

Proper function of receptors on the cell surface is essential for homeostasis. Compounds that target cell surface receptors to address dysregulation have proven exceptionally successful as therapeutic agents; however, the development of compounds with the desired specificity for receptors, cells, and tissues of choice has proven difficult in some cases. The use of compounds that can engage more than one binding site at the cell surface offers a path toward improving biological specificity or pharmacological properties. In this chapter we summarize historical context for the development of such bivalent compounds. We focus on developments in chemical methods and biological engineering to provide bivalent compounds in which the high affinity and specificity of antibodies are leveraged to create multifunctional conjugates with new and useful properties. The development of methods to meld biological macromolecules with synthetic compounds will facilitate modulation of receptor biology in ways not previously possible.

Indexed as

Antibodies, BispecificBiologyMembrane ProteinsAntibodies, BispecificMembrane ProteinsAntibodyAntibody-drug conjugateBispecificChemical biologyGPCRNanobodyReceptorVHH

Identifiers

PMID34752333
PMCPMC8895325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.